Pattern, Variation and Outcomes of Opioid Prescription in Older Adults

老年人阿片类药物处方的模式、变化和结果

基本信息

批准号：
9518779
负责人：
Yong-Fang Kuo
金额：
$ 34.88万
依托单位：
UNIVERSITY OF TEXAS MED BR GALVESTON
依托单位国家：
美国
项目类别：
财政年份：
2016
资助国家：
美国
起止时间：
2016-09-15 至 2020-06-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9518779
关键词：
Acute Address Affect Age Alabama Alaska Benzodiazepines Cessation of life Chronic Chronic low back pain Classification Clinical Clinical Practice Guideline Codeine Comorbidity Confusion Data Degenerative polyarthritis Development Dose Effectiveness Elderly Emergency department visit Ensure Equilibrium Exposure to Formulation Foundations Fracture Guidelines High Prevalence Hospitalization Hydrocodone Institutionalization Intervention Investigation Kidney Calculi Knowledge Lead Malignant Neoplasms Medical Medicare Medicare claim Morbidity - disease rate New Jersey Operative Surgical Procedures Opiate Addiction Opioid Opioid Analgesics Outcome Outpatients Pain Pain management Patients Pattern Pharmaceutical Preparations Pharmacists Policies Population Prevalence Primary Care Physician Provider Public Health Public Policy Regulation Reporting Research Design Retrospective cohort study Risk Safety Schedule Selection Bias Texas Toxic effect Tramadol Variant addiction adverse outcome age related aged beneficiary cancer diagnosis clinical practice cohort drug metabolism experience falls federal policy insight interest longitudinal analysis mortality multilevel analysis non-cancer chronic pain non-cancer pain older patient opioid epidemic opioid mortality opioid overdose opioid use overtreatment prescription opioid programs public health relevance response

项目摘要

DESCRIPTION (provided by applicant): Concerns have been raised about the safety and effectiveness of opioid analgesics for chronic non-cancer pain in view of a threefold increase in opioid prescribing and a dramatic increase in the rates of opioid-related adverse outcomes. Our preliminary data showed the rate of opioid prescriptions for older adults varied dramatically across states, from 2.7% in Texas to 14.5% in Alaska for schedule II and from 11.7% in New Jersey to 34.8% in Alabama for schedule III. We also found exceedingly high variability in prescribing schedule II/III opioids among primary care physicians (PCPs); the percentage of PCPs prescribing opioids to their non-cancer patients ranged from 0.4% to 70.5%. Twenty-three percent of the variance in whether an elderly patient received an opioid was explained by which PCP the patient saw. Such high variation in opioid prescribing-even after adjustment for patient mix-offers critical insight into the complexity and confusion surrounding this issue. On any given day, providers-faced with difficult decisions about treating patients with severe pain-must carefully balance the risks of overtreatment versus undertreatment. To date, no nationally representative studies have examined variations in the use of opioids in older adults and their relationship to outcomes, different state regulations, and federal policy. Our Specific Aims are: 1. Examine temporal changes in the prevalence, duration, and dose of opioid use in older adults, with particular focus on the impact of policy changes. 2. Assess the variation of opioid use across providers and determine patient and provider factors associated with opioid use in older adults. 3. Examine the risk of adverse outcomes-including falls, fractures, emergency room (ER) visits, hospitalization, institutionalization, and mortality-in older patients receiving opioids. We will use 2007-2015 100% national data on Medicare beneficiaries to investigate this escalating public health crisis. The proposed investigation will provide data that can lead to improvements in public policy and clinical practice guidelines for ensuring safe and effective use of opioids in older adults.

描述（由适用提供）：鉴于OOID处方增加了三倍，并且与OOID相关的不良结果率显着提高，因此对Ooid镇痛药对慢性非癌症疼痛的安全性和有效性提出了担忧。我们的初步数据显示，各州的老年人的OOID处方率差异很大，从德克萨斯州的2.7％到阿拉斯加的附表II的14.5％，从新泽西州的11.7％到附表III的阿拉巴马州的34.8％。我们还发现，在初级保健医生（PCP）中开处方II/III OIDS的规定方案极高的可变性；向非癌症患者处方OOID的PCP百分比在0.4％至70.5％之间。患者在哪个PCP上解释了年长的患者是否接受过OOID的差异的23％的差异。 OID处方的这种高度差异，即使在调整患者混合商后，也要对围绕此问题的复杂性和混乱进行批判性洞察力。在任何一天，提供者都面临着艰难的决定，即治疗严重疼痛的患者仔细平衡过度治疗与不足的风险。迄今为止，尚无全国代表性研究检查老年人使用OOID的差异及其与结果，不同州法规和联邦政策的关系。我们的具体目的是：1。检查老年人中阿片类药物使用率，持续时间和剂量的暂时变化，特别关注政策变化的影响。 2。评估提供者跨提供者的阿片类药物使用的变化，并确定与老年人使用阿片类药物相关的患者和提供者的因素。 3。检查不良结果的风险，包括跌倒，裂缝，急诊室（ER）就诊，住院，制度化和接受阿片类药物的老年患者。我们将使用2007年至2015年的100％关于Medicare受益人的国家数据来调查这一不断上升的公共卫生危机。拟议的投资将提供数据可以改善公共政策和临床实践指南，以确保老年人安全有效地使用阿片类药物。